Evidence Hub

Targeting FoxO1-STX17-mediated autophagic flux: Quercetin's therapeutic mechanism in diabetic nephropathy

Hou B, Li Y, Tang J, Cao X, Zhang S, Cai Y, Guo J, Xi J et al.

European journal of pharmacology, 2025

Abstract

BACKGROUND: Diabetic nephropathy (DN) involves autophagic stress from defective lysosomal clearance. Quercetin, a flavonol, shows therapeutic potential but its mechanism remains unclear.

OBJECTIVE: Investigate quercetin's role in DN via FoxO1-STX17-mediated autophagosome-lysosome fusion.

METHODS: DN was induced in C57BL/6J mice (uninephrectomy + streptozotocin [50 mg/kg]). Quercetin (150 mg/kg/day) or valsartan (40 mg/kg/day) was administered for 12 weeks. Renal function, histopathology, and autophagy markers (p62, LC3-II, STX17) were evaluated. Quercetin metabolites were identified via UPLC-HRMS. Network pharmacology, molecular docking, dynamics (MD), and biolayer interferometry (BLI) validated targets. Advanced glycation end products (AGE) (100 μg/mL)-stimulated podocytes, Bafilomycin (Baf)-A1-treated and FoxO1-silenced podocytes were used for mechanistic validation.

RESULTS: In vivo, quercetin ameliorated renal injury and restored autophagic flux without affecting upstream autophagy initiation. Ten quercetin-derived metabolites were identified in serum. Bioinformatics analysis nominated FoxO1 as a key regulator of quercetin-modulated autophagy. In vitro, quercetin protected podocytes and promoted autophagosome-lysosome fusion, effects that were reversed by Baf-A1 and replicated in FoxO1-silenced cells.

CONCLUSION: Quercetin alleviates DN by targeting FoxO1 to restore STX17-dependent autophagosome-lysosome fusion, thereby resolving autophagic stress. These findings support…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free